Aducanumab

From Ganfyd

Jump to: navigation, search
Aducanumab is a human recombinant anti-beta amyloid monoclonal antibody[1]. It is in Phase III testing to treat Alzheimer's disease and is a member of the EMEA's PRIority MEdicines (PRIME) scheme for breakthrough therapies. It will be a test for the amyloid hypothesis[2] aetiology for the memory deficits of Alzheimer's disease as by August 2016 it had been shown to remove pathology associated proteins from the human brain[3]

Contents

Delivery

  • Monthly intravenous infusions

Side effects

  • Headache

Pharmacology

Reduces soluble and insoluble amyloid

References